Media Room Menu
THE ELOXATIN®-BASED REGIMEN (FOLFOX4) SIGNIFICANTLY IMPROVED PROGRESSION FREE SURVIVAL WHEN GIVEN BEFORE AND AFTER SURGERY IN PATIENTS WITH RESECTABLE LIVER METASTASES FROM COLORECTAL CANCER
